CorMedix Inc. (CRMD), a biopharmaceutical company, announced financial results for the fourth quarter and full-year 2025 with revenue growth. In addition, the firm reaffirmed full-year 2026 guidance.
For the fourth quarter, net income was $14.02 million, or $0.16 per share, compared with $13.46 million, or $0.20 per diluted share, in the prior year.
Revenue jumped to $128.62 million from $31.21 million in the year ago. This comprised of $91.2 million in sales of DefenCath and $37.4 million in revenue associated with the acquired Melinta Therapeutics portfolio.
For the full year 2025, the firm swung to a net income of $163.06 million, or $2.04 per diluted share, compared with a net loss of $17.93 million, or $0.30 per share, in the prior year.
Total revenue improved to $311.71 million from $43.47 million in the year ago period.
At December 31, 2025, cash and short-term investments amounted to $148.5 million.
Looking ahead to the full year 2026, CorMedix reiterates net revenue in the range of $300 to $320 million, compared to $311.71 million in 2025.
And adjusted EBITDA is expected to be between $100 and $125 million.
Pipeline and Milestones Ahead
CorMedix's lead product is DefenCath (taurolidine and heparin), a catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition(TPN) and pediatric patient populations, and also intends to develop DefenCath as a catheter lock solution for use in other patient populations.
Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercialising anti-infective products, including
-REZZAYO to treat candidemia and invasive candidiasis.
-KIMYRSA and ORBACTIV are oritavancin products indicated for the treatment of adult patients with acute bacterial skin and skin structure infections.
-VABOMERE for complicated urinary tract infections.
-MINOCIN (minocycline) for the treatment of infections.
-TOPROL-XL is used to treat high blood pressure, chest pain or discomfort due to coronary heart disease (angina pectoris), and heart failure.
-BAXDELA for the treatment of acute bacterial skin and skin structure infections.
Currently, CorMedix has two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN.
CorMedix expects clinical data from the Phase 3 ReSPECT study of REZZAYO (rezafungin for injection) in the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplant in the second quarter of 2026.
In addition, the ongoing Phase 3 study of DefenCath catheter lock solution in TPN patients continues to enrol patients with targeted completion in the first half of 2027.
CRMD has traded between $5.60 and $17.43 in the prior year. The stock closed Thursday's trade at $6.30.down 11.52%.
In the overnight market, CRMD is up 1.59%.at $6.40
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.